Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA134616
Max Phase: Preclinical
Molecular Formula: C16H10F3N3O4S
Molecular Weight: 397.33
Molecule Type: Small molecule
Associated Items:
ID: ALA134616
Max Phase: Preclinical
Molecular Formula: C16H10F3N3O4S
Molecular Weight: 397.33
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COC(=O)Nc1nc2cc(C(=O)c3cc(C(=O)C(F)(F)F)cs3)ccc2[nH]1
Standard InChI: InChI=1S/C16H10F3N3O4S/c1-26-15(25)22-14-20-9-3-2-7(4-10(9)21-14)12(23)11-5-8(6-27-11)13(24)16(17,18)19/h2-6H,1H3,(H2,20,21,22,25)
Standard InChI Key: RZXMCOSXLCPHLU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 397.33 | Molecular Weight (Monoisotopic): 397.0344 | AlogP: 3.78 | #Rotatable Bonds: 4 |
Polar Surface Area: 101.15 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 9.11 | CX Basic pKa: 3.34 | CX LogP: 3.86 | CX LogD: 3.86 |
Aromatic Rings: 3 | Heavy Atoms: 27 | QED Weighted: 0.65 | Np Likeness Score: -1.16 |
1. Kruse LI, Ladd DL, Harrsch PB, McCabe FL, Mong SM, Faucette L, Johnson R.. (1989) Synthesis, tubulin binding, antineoplastic evaluation, and structure-activity relationship of oncodazole analogues., 32 (2): [PMID:2913301] [10.1021/jm00122a020] |
Source(1):